Tag: Lupin

Lupin Discussing Sale of Kyowa Pharmaceuticals for $600m

India’s Lupin Ltd is in advanced talks to sell its Japanese generics subsidiary Kyowa Pharmaceuticals for an enterprise value of $600 million to a local player as it steps up efforts to significantly ...

BI Announce $700m Deal for Lupin’s MEK Inhibitor Compound

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794. The p...

Lupin Launches Generic of Novartis’ Gleevec®

Lupin Limited (Lupin) announced the launch of Imatinib Mesylate Tablets, 100 mg (base) and 400mg (base). Lupin's alliance partner Natco had received an approval from the United States Food and Drug Ad...

FDA Approved Lupin’s Generic of Pfizer to Market

Pharma major Lupin announced that it has received approval for its Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, from the United States Food and Drug Administration (FDA) to market...

EC Approved Indian Orphan Drug

The European Commission (EC) has approved NaMuscla (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders from Indian drugmaker Lupin. Non-dys...

Lupin Plans to Develop First-to-Market Products

Drug maker Lupin is in the process of developing a pipeline of products under its new drug discovery programme to treat various diseases like cancer and metabolic disorders, a top company official sai...